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INTRODUCTION
The oral administration of the bile acids cheno-
deoxycholic acid (CDCA) (1) and ursodeoxycholic
acid (UDCA) (2,3) reduces the cholesterol saturation
index (SI) in fasting gallbladder bile and aids in
the solubilization of cholesterol-derived gallstones.
Northfield and co-workers reported a significant
increase in the rate of gallstone dissolution in patients
who were administered CDCA at bedtime, along
with a low cholesterol diet, compared with CDCA
administration at mealtime, along with an unrestricted
diet. (4) Moreover, when the latter investigators
compared the results of CDCA administration for
mealtime vis-a-vis bedtime administration, as well as
for UDCA, along with an unrestricted diet, bedtime
administration significantly enhanced the rate of
gallstone dissolution. They also proposed the bedtime
regimen as an appropriate strategy for reducing
the minimum effective dose of CDCA required to
desaturate gallbladder bile with cholesterol, (5) and
demonstrated the utility of bedtime UDCA admin-
istration in dissolution therapy in a randomized
study. (6) Lanzini et al . reported that a reduced
UDCA dose (7mg/kg/day) given at bedtime was as
effective as the conventional 10mg/kg/day UDCA
given at mealtime for reducing the cholesterol SI in
gallbladder bile in individual patients. (7) Moreover,
UDCA is generally preferred over CDCA for use
in gallstone dissolution in contrast to the latter bile
acid, (8, 9) because it does not cause diarrhea and
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hypertransaminasemia. (10)
Therefore, in the U.S. and Europe, bedtime UDCA
administration is generally thought to be more
effective than mealtime administration of the same
total daily dose in enhancing the rate of dissolution
of gallstone. However, in Japan, UDCA at 600 mg/
day is conventionally divided into 3 doses, which
is given at mealtimes. Moreover, gallstones which
are composed largely of calcium bilirubinate are
generally more common than in western countries,
and pigment stone formation is especially prominent.
(11) These findings suggest that Asian subjects may
respond differently to western subjects, in terms
of cholesterol SI, to the administration of UDCA.
However, little information on the cholesterol SI in
hepatic bile in Japanese patients with gallstone is
available for comparison between bedtime and meal-
time administration of UDCA, although Shibata et
al . (12) reported on the utility of bedtime adminis-
tration.
The present paper describes a study in which
the bedtime administration of UDCA is alternated
with mealtime administration in Japanese patients
with gallstone and choledocholithiasis who were
undergoing biliary drainage. The patients received a
routine hospital diet, and hepatic bile was collected
from a drainage tube retained retrograde in the
common bile duct, after an appropriate time lapse,
and the cholesterol SI and the bile acid composition
were compared for the two protocols.
SUBJECTS AND METHODS
Subjects
Six patients [3 men and 3 women ; mean age
(±SD), 60±11 yr ; mean body weight (±SD), 53±
6 kg] with gallstone and choledocholithiasis were
studied (Table1). All patients were treated to improve
jaundice by undergoing biliary drainage at Second
Department of Internal Medicine, Tokushima Uni-
versity Hospital, and Tokushima Municipal Hospital.
For biliary drainage, endoscopic nasotracheal biliary
drainage was carried out by retaining a drainage
tube (Create Medic Co., Tokyo, Japan, 7F) retrograde
in the common bile duct. Prior to the study, the
objectives were explained to each patient and written
informed consent was obtained. The analytical
schedule was started for each patient when his/
her aspartate aminotransferase (AST) and alanine
aminotransferase (ALT) levels were 100 IU/L or
less and serum total bilirubin was 3 mg/dl or less,
and no other serious functional disorder was observed.
During the experimental course all patients received
a standard hospital diet.
Methods
UDCA was synthesized by Tokyo Tanabe Phar-
maceutical Co. (Tokyo, Japan), and was at least 99%
pure, as evidenced by gas liquid chromatography
and thin layer chromatography. Fig.1 shows the
protocol for UDCA administration and the schedule
for bile collection from the biliary drainage tube.
On a body weight basis, the daily UDCA dose ranged
from 10.0 to 12.8mg/kg for the 6 individual subjects,
with a mean value (±SD) of 11.3±1.1 mg/kg/day
(Table 1). On the first day of study when UDCA
was not administered, bile was collected 13 times
every 3 h for a total period of 39 h (Before UDCA).
UCDA at 600 mg was administered once at bed-
time the next day. On the third day, bile was also
collected 13 times every 3 h (Bedtime UDCA). At
58 h after the bedtime administration of UDCA,
another 600 mg, divided into 3 doses of 200 mg each,
Fig.1. UDCA administration method and the schedule for bile collection from the biliary drainage tube. The drainage tube was
retained retrograde in the common bile duct in individual subjects. Hepatic bile was collected 13 times at 3 h intervals during a 39 h
period without UDCA administration (Before UDCA). A 600 mg dose of UDCA was given once the next day at bedtime, and
hepatic bile was collected as described above (Bedtime UDCA). From 58 h onwards, another 600 mg which was divided into 3-200 mg
doses a day at mealtime was given, and hepatic bile was again collected during the 39 h period (Mealtime UDCA). All subjects
received a routine hospital diet during the course of bile collection.
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was administered at mealtimes. Bile was again
collected 13 times every 3 h from the 5 th to the
6 th day (Mealtime UDCA). Bile obtained from the
drainage tubes was frozen and stored at -80℃ until
assayed.
For determination of the cholesterol SI of hepatic
bile, total cholesterol (13) and total bile acids (14,
15) were measured enzymatically. Phospholipids
were extracted (16) and determined colorimetrically.
(17) The SI was calculated by the formula established
by Thomas and Hofmann, (18) based on the limits
of cholesterol solubility defined by Hegardt and
Dam (19) and Holzbach et al. (20) The determi-
nation of individual bile acids was carried out by
high-performance liquid chromatography (HPLC)with
a post-column enzymatic reaction and fluorescence
detection. (21)
Statistics
Data obtained from each collection period before
UDCA administration, during bedtime administra-
tion and mealtime administration were expressed
as the mean (±SD) of the individual bile collected
13 times over an interval of 3 h to 39 h unless otherwise
indicated. Statistical significance was tested with
the Mann-Whitney U test, and p values <0.05 were
accepted to indicate significant differences.
RESULTS
Changes in bile acid composition
Changes in the differential amount of bile acid in
hepatic bile before UDCA administration, and during
bedtime administration and mealtime administration
in patients with gallstone and choledocholithiasis
are shown in Figs. 2 and 3. Prior to UDCA admin-
istration, the concentrations of UDCA in bile ranged
from 0.0 to 0.08 mol/l for the 6 individual subjects
with a mean value of 0.01±0.03 mol/l. The UDCA
level increased rapidly for 12 h after the bedtime
administration and returned to baseline by at least
36 h after bedtime administration (Fig.2). Thus,
there was no additive influence of the initially ad-
ministered UDCA on bile acid compositions at 58 h
after bedtime administration, at which time an
additional 600 mg was administered in 3-200 mg
doses at mealtimes. The total bile acid (TBA) levels
in bile before administration, and during bedtime
administration and mealtime administration were
85.6±35.4, 108.6±31.2 and 120.5±48.0 mol/l, re-
spectively, and no significant differences among the
three interval values were observed. The respective
values of cholic acid (CA) were 45.7±15.5, 40.7±
12.2 and 53.0±21.9 mol/l ; CDCA, 37.9±13.3, 29.7
±11.4 and 47.6±15.4 mol/l ; deoxycholic acid (DCA),
1.3±1.3, 0.7±0.5 and 0.8±0.6 mol/l ; UDCA, 0.3
±0.3, 37.3±10.6 and 18.6±6.5 mol/l ; lithocholic
acid (LCA), 0.03±0.04, 0.0 and 0.0 mol/l. The levels
of DCA and LCA during the experimental course
were negligible. The levels of CA and CDCA tended
Table 1. Patients studied with gallstone and choledocholithiasis
Patient no.
Age
Yr
Sex
Dose of UDCA
mg/day mg/kg/day
Disease
1 68 M 600 12.8 Gallstone and Choledocholithiasis
2 43 M 600 10.9 Gallstone and Choledocholithiasis
3 73 F 600 11.1 Gallstone and Choledocholithiasis
4 68 M 600 12.5 Gallstone and Choledocholithiasis
5 58 F 600 10.0 Gallstone and Choledocholithiasis
6 52 F 600 10.7 Gallstone and Choledocholithiasis
All patients were treated by undergoing endoscopic nasobiliary drainage for the purpose of improving jaundice and received a
routine hospital diet during the course of biliary drainage.
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to decrease during bedtime UDCA administration,
but not during mealtime administration, although
the differences in the mean interval values of CDCA
or CA were not significant. While the UDCA levels
increased significantly during both bedtime and
mealtime administrations compared to those before
administration, the effect of bedtime administra-
tion was significantly greater (Fig.3).
Alterations in conjugated bile acids
The alterations in conjugated CA and CDCA in
hepatic bile before and during UDCA administra-
tion at bedtime and mealtime are shown in Fig.4.
The glycine conjugated CA levels before admin-
istration, and during bedtime administration and
mealtime administration were 34.0±11.7, 29.1±10.1
and 37.7±12.8 mol/l, respectively. The respective
values of taurine conjugates were 11.7±4.6, 9.0±3.5
and 12.7±5.8 mol/l and those of the non-conjugation
variety were 0.02±0.03, 2.6±1.4 and 2.6±1.6mol/l.
In the case of CDCA, the respective values of the
glycine conjugates were 30.8±12.9, 22.7±8.9 and
38.2±13.4 mol/l ; the taurine conjugates, 7.1±2.9,
5.0±1.8 and 9.1±3.4 mol/l ; non-conjugation type,
0.1±15.8, 16.0±17.9 and 2.0±16.9 mol/l. While
the levels of non-conjugated CA and CDCA had a
tendency to increase, the levels of glycine-conjugated
CA and CDCA tended to decrease during bedtime
UDCA administration (Fig.4), although the differ-
ences were not significant.
Alterations in cholesterol SI
Changes of the cholesterol SI in hepatic bile
Fig.2. Profiles for UDCA levels at intervals of 3 h in hepatic bile from 2 subjects (○, patient No.1 ; ●, patient No.4) studied on
6 successive days.
Fig.3. Mean interval values of bile acid compositions in hepatic
bile from 6 subjects before and during UDCA administration
at bedtime and mealtime. Bile was collected 13 times at 3 h
intervals over a 39 h period before UDCA administration and
during UDCA administration at bedtime and mealtime. Bile
acid composition in the collected bile was determined by HPLC
with a post-column enzymatic reaction and fluorescence detection.
*Significant difference between values before and during UDCA
administration (P<0.05).†Significant difference between values
during UDCA administration at bedtime and mealtime (P<0.05).
□, Before administration ; □, bedtime administration ; □, meal-
time administraion.
・・・・・・・・・・・・
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before and during UDCA administration at bedtime
and mealtime are shown in Figs.5 and 6. The mean
interval values for cholesterol SI during the period
of 39 h in all the 6 subjects, before administration,
during bedtime administration and during mealtime
administration were 2.4±0.5, 1.6±0.3 and 1.9±0.4,
respectively. The mean values decreased duringUDCA
administration both at bedtime and mealtime : the
difference between the values for before and during
bedtime administration were significant, but the
difference between the values before and during
mealtime was not.
DISCUSSION
It has been reported that, for the case of bile acid
composition after UDCA administration to patients
with gallstones, UDCA concentrations in the fasting
gallbladder bile generally increase in proportion to
the dose, and that levels of CA, CDCA and DCA
decrease while LCA levels remain unchanged. (18)
The results of this study also indicate a significant
increase in UDCA levels in hepatic bile obtained
from patients with gallstone and choledocholithiasis
after UDCA administration, both at bedtime and at
mealtime. The effect of bedtime administration was
significantly greater than that of mealtime admin-
istration. It is worth noting that the hepatic bile
levels of CA and CDCA tended to decrease during
bedtime UDCA administration, but not during
mealtime administration, and that the levels of DCA
and LCA were negligible throughout the experiment,
although the differences between the mean interval
values were not significant. The findings herein
are consistent with findings reported byMakino and
Nakagawa, who reported analyses of gallbladder
bile from Japanese patients. (22)
In regard to CA and CDCA, we investigated differ-
ences in the levels of glycine- and taurine-conjugated
type levels, as a result of UDCA administration at bed-
time and mealtime. The levels of glycine-conjugated
CA and CDCA were not significantly decreased
during bedtime UDCA administration. Tanimura
et al . (23) also reported that, compositionally, no
difference in the levels of conjugated bile acids
between cholesterol gallstone patients and normal
controls was evident. These findings suggest that
conjugated bile acid composition is not affected by
UDCA administration or gallstone formation.
To simply illustrate the correlation between bile
acid, cholesterol and phospholipid in bile, Admirand
and Small proposed a triangular drawing, the sides
of which represent the molar ratio of these 3 param-
eters. (24) In addition, Metzger et al . were able to
calculate the extent of gallstone formation from the
dissolved status of these 3 parameters in terms of
cholesterol SI, (25) and Thomas and Hofmann (18)
derived a formula for the calculation of SI. In the
present study, the cholesterol SI in hepatic bile
decreased after UDCA administration at bedtime
and mealtime, which is consistent with the results
of studies on gallbladder bile reported to date in
western countries. (26-28) It is noteworthy that the
SI in hepatic bile was significantly lower for bedtime
administration, compared to mealtime administra-
tion. Coyne (29) and Maton et al . (30) reported that
treatment with bile acids induced a decrease in
HMG-CoA reductase, a rate determining enzyme
in the biosynthesis of cholesterol in the liver, as
one of the pharmacological effects of bile acids, that
Fig.4. Mean interval values of conjugated CA (upper panel)
and CDCA (lower panel) in hepatic bile from 6 subjects before
and during UDCA administration at bedtime and mealtime. Bile
was collected 13 times at 3 h intervals over a 39 h period before
UDCA administration and during UDCA administration at bed-
time and mealtime. Conjugated bile acids in the collected bile were
determined by HPLC with a post-column enzymatic reaction and
fluorescence detection.
□, Glycine conjugation variety ; □, Taurine conjugation variety ;
■, Non-conjugation variety.
・・・・・・・・・・・・
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cholesterol excretion in the liver was decreased in
patients with cholesterol gallstones, and that this
improved the SI and induced litholysis. Moreover,
Northfield et al . reported that bile acid treatment
was more efficient when the administration was
daily at bedtime because hepatic bile with a higher
SI is secreted at night. (5) Lanzini et al. (7) concluded
that an increase in biliary cholesterol saturation
could be expected as a result of bedtime adminis-
tration, an observation which could lead to dose
reduction. A statistical significance for the decreased
cholesterol SI in hepatic bile was observed in this
study during UDCA bedtime administration, as
compared to mealtime administration, suggesting
a decreased cholesterol excretion into hepatic bile.
However, it should be noted that cholesterol sol-
ubility in hepatic bile is now known to be largely
determined by cholesterol-phospholipid vesicles
(31, 32). In fact, the cholesterol SI is nearly always
in excess of 1 in hepatic bile, indicating that mixed
micelles are always supersaturated in a diluted
system, such as hepatic bile. These vesicles are then
micellized by bile salts as bile becomes concentrated
in the bile ducts and further in the gallbladder.
Although the cholesterol SI in gallbladder bile is
considered to be a lithogenic index in patients with
cholesterol gallstone, the significance of the cho-
lesterol SI in hepatic bile in the formation of
cholesterol gallstone remains to be elucidated.
Fig.5. Profiles for cholesterol SI at intervals of 3 h in hepatic bile from 2 subjects (○, patient No.1 ; ●, patient No.4) studied on 6
successive days.
Fig.6. Mean interval values [ , ±SD ( )] of cholesterol
SI in hepatic bile from 6 subjects before and during UDCA
administration at bedtime and mealtime. Bile was collected 13
times at 3 h intervals over a 39 h period before UDCA adminis-
tration and during UDCA administration at bedtime andmealtime.
Cholesterol SI in the collected bile was calculated by the
formula established by Thomas and Hofmann. (17). *Significant
difference between values before and during UDCA adminis-
tration (P<0.05).
○, patient No.1 ; □, patient No.2 ; △, patient No.3 ; ●, patient
No.4 ; ■, patient No.5 ; ▲, patient No.6.
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Based on these, and other findings together which
show a diminished SI in bile, UDCA administra-
tion at bedtime is more useful in patients with
gallstone and choledocholithiasis both in Japan and
western countries. Accordingly, it is reasonable to
assume that this effect of bedtime UDCA adminis-
tration may account not only for its greater potency
in comparison with equimolar mealtime UDCA
administration but also for the reduction of the
minimum effective dose in achieving consistent
desaturation of gallbladder bile with cholesterol.
In Japan, many patients with gallstone for which
litholysis treatment is indicated, have silent stones,
which require the intake of bile acids over a pro-
longed period. For this issue, the problem is how
to improve compliance and to support gallstone
dissolution with minimum incidences of dose-related
side effects. Although no data on the minimum
effective dose of UDCA is available at present,
compared with administration 3 times per day, a
single, daily administration at bedtime appears to
be a more effective protocol, since better compliance
would be expected for this protocol.
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